MIT Chemists Develop Targeted Cancer Therapy Using Tiny Particles

Strategic Insights -

MIT chemists have developed a new targeted cancer therapy using tiny particles called nanoparticles that can deliver a large range of chemotherapy drugs directly to tumor cells. The new therapy, which is guided by antibodies that target specific tumor proteins, uses bottlebrush-shaped polymer chains carrying dozens or hundreds of drug molecules, significantly increasing the payload compared to existing antibody-drug conjugates. In mouse models of breast and ovarian cancer, the researchers found that treatment with these conjugated particles could eliminate most tumors. The potential of this technology to provide more effective therapies for cancer patients is being hailed as a significant breakthrough.

Key Takeaways:

  • The new nanoparticles are designed to deliver a large range of chemotherapy drugs directly to tumor cells, reducing the side effects of treatment.
  • The particles are guided by antibodies that target specific tumor proteins, allowing for precise targeting of cancer cells.
  • The payload of the particles can be adjusted to carry dozens or hundreds of drug molecules, significantly increasing the efficacy of treatment.
  • The new therapy has shown promising results in mouse models of breast and ovarian cancer, with the ability to eliminate most tumors.
  • The technology has the potential to provide more effective therapies for cancer patients by increasing the customizability of the particles and the variety of drug combinations that can be used.
  • The researchers plan to try delivering combinations of drugs that work by different mechanisms, which could enhance their overall effectiveness.
  • The technology can be modified to target other types of cancer by swapping in different antibodies.

Statistics:

  • The nanoparticles can carry dozens or hundreds of drug molecules, significantly increasing the payload compared to existing antibody-drug conjugates.
  • The researchers found that treatment with these conjugated particles could eliminate most tumors in mouse models of breast and ovarian cancer.
  • The payload of the particles can be adjusted to carry 2-3 bottlebrush polymers attached to a single tumor-targeting antibody, creating a single antibody-bottlebrush conjugate (ABC) that can carry multiple drugs in specific ratios.
  • The currently approved ADCs can carry a maximum of about 8 drug molecules.
  • The researchers used a low dose of the ABC particles, almost 100 times lower compared to traditional small-molecule drugs, and still achieved better efficacy.

Sources:

  • Massachusetts Institute of Technology (MIT) press release: "MIT chemists develop targeted cancer therapy using tiny particles".
  • Nature Biotechnology: "Antibody-drug conjugates with large payloads carried on bottlebrush polymers".
  • Johnson et al. (2023). Antibody-drug conjugates with large payloads carried on bottlebrush polymers. Nature Biotechnology, doi: [insert DOI].
  • National Institutes of Health.
  • Ludwig Center at MIT.
  • Koch Institute Frontier Research Program.